Rivaroxaban in patients stabilized after a ST-segment elevation myocardial infarction: results from the ATLAS ACS-2-TIMI-51 trial (Anti-Xa Therapy to Lower Cardiovascular Events in Addition to Standard Therapy in Subjects with Acute Coronary Syndrome-Thrombolysis In Myocardial Infarction-51).
暂无分享,去创建一个
A. Parkhomenko | J. Mega | E. Braunwald | S. Murphy | M. Tendera | C. Gibson | P. Widimsky | R. Kiss | A. Plotnikov | P. Burton | C. Gibson